Lysosomal enzyme can bypass the blood-brain barrier and reach the CNS following intranasal administration

Molecular Genetics and Metabolism

Volumn 106, Issue 1, 2012, Pages 131-134

  Wolf, Daniel A ^a   Hanson, Leah R ^b   Aronovich, Elena L ^a   Nan, Zhenhong ^a   Low, Walter C ^a   Frey, William H ^b   McIvor, R Scott ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

Adeno associated virus; Alpha l iduronidase; Blood brain barrier; Intranasal delivery; Mucopolysaccharidosis; Neurological disease

Indexed keywords

LARONIDASE; LEVO IDURONIDASE; LYSOSOME ENZYME; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; LYSOSOME STORAGE DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CENTRAL NERVOUS SYSTEM; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; IDURONIDASE; LYSOSOMES; MICE; MICE, TRANSGENIC; MUCOPOLYSACCHARIDOSIS I; RECOMBINANT PROTEINS;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84860138173     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.02.006     Document Type: Article

References (26)

1. Shingaki T., Inoue D., Furubayashi T., Sakane T., Katsumi H., Yamamoto A., Yamashita S. Transnasal delivery of methotrexate to brain tumors in rats: a new strategy for brain tumor chemotherapy. Mol. Pharm. 2010, 7:1561-1568.
2. Danielyan L., Schafer R., von Ameln-Mayerhofer A., Buadze M., Geisler J., Klopfer T., Burkhardt U., Proksch B., Verleysdonk S., Ayturan M., Buniatian G.H., Gleiter C.H., Frey W.H. Intranasal delivery of cells to the brain. Eur. J. Cell Biol. 2009, 88:315-324.
3. Danielyan L., Schafer R., von Ameln-Mayerhofer A., Bernhard F., Verleysdonk S., Buadze M., Lourhmati A., Klopfer T., Schaumann F., Schmid B., Koehle C., Proksch B., Weissert R., Reichardt H.M., van den Brandt J., Buniatian G.H., Schwab M., Gleiter C.H., Frey W.H. Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res. 2011, 14:3-16.
4. Draghia R., Caillaud C., Manicom R., Pavirani A., Kahn A., Poenaru L. Gene delivery into the central nervous system by nasal instillation in rats. Gene Ther. 1995, 2:418-423.
5. Lemiale F., Kong W.P., Akyurek L.M., Ling X., Huang Y., Chakrabarti B.K., Eckhaus M., Nabel G.J. Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J. Virol. 2003, 77:10078-10087.
6. Jerusalmi A., Morris-Downes M.M., Sheahan B.J., Atkins G.J. Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol. Ther. 2003, 8:886-894.
7. Laing J.M., Gober M.D., Golembewski E.K., Thompson S.M., Gyure K.A., Yarowsky P.J., Aurelian L. Intranasal administration of the growth-compromised HSV-2 vector DeltaRR prevents kainate-induced seizures and neuronal loss in rats and mice. Mol. Ther. 2006, 13:870-881.
8. Born J., Lange T., Kern W., McGregor G.P., Bickel U., Fehm H.L. Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 2002, 5:514-516.
9. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J. Pharm. Sci. 2009, 98:2501-2515.
10. Vaka S.R., Sammeta S.M., Day L.B., Murthy S.N. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J. Pharm. Sci. 2009, 98:3640-3646.
11. Capsoni S., Covaceuszach S., Ugolini G., Spirito F., Vignone D., Stefanini B., Amato G., Cattaneo A. Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice. J. Alzheimers Dis. 2009, 16:371-388.
12. Alcalay R.N., Giladi E., Pick C.G., Gozes I. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci. Lett. 2004, 361:128-131.
13. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations J. Pharm. Sci. 2010, 99:1654-1673.
14. Zhu W., Cheng S., Xu G., Ma M., Zhou Z., Liu D., Liu X. Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia. Drug Deliv. 2011, 18:338-343.
15. Zhao H.M., Liu X.F., Mao X.W., Chen C.F. Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin. Med. Sci. J. 2004, 19:257-261.
16. Ohmi K., Greenberg D.S., Rajavel K.S., Ryazantsev S., Li H.H., Neufeld E.F. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1902-1907.
17. Wolf D.A., Lenander A.W., Nan Z., Belur L.R., Whitley C.B., Gupta P., Low W.C., McIvor R.S. Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neurobiol. Dis. 2011, 43:123-133.
18. Garcia-Rivera M.F., Colvin-Wanshura L.E., Nelson M.S., Nan Z., Khan S.A., Rogers T.B., Maitra I., Low W.C., Gupta P. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res. Bull. 2007, 74:429-438.
19. Aronovich E.L., Bell J.B., Khan S.A., Belur L.R., Gunther R., Koniar B., Schachern P.A., Parker J.B., Carlson C.S., Whitley C.B., McIvor R.S., Gupta P., Hackett P.B. Systemic correction of storage disease in MPS I NOD/SCID mice using the sleeping beauty transposon system. Mol. Ther. 2009, 17:1136-1144.
20. Giugliani R., Rojas V.M., Martins A.M., Valadares E.R., Clarke J.T., Goes J.E., Kakkis E.D., Worden M.A., Sidman M., Cox G.F. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol. Genet. Metab. 2009, 96:13-19.
21. Dhuria S.V., Hanson L.R., Frey W.H. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J. Pharm. Sci. 2010, 99:1654-1673.
22. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14777-14782.
23. Kakkis E.D., McEntee M.F., Schmidtchen A., Neufeld E.F., Ward D.A., Gompf R.E., Kania S., Bedolla C., Chien S.L., Shull R.M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 1996, 58:156-167.
24. Vite C.H., Wang P., Patel R.T., Walton R.M., Walkley S.U., Sellers R.S., Ellinwood N.M., Cheng A.S., White J.T., O'Neill C.A., Haskins M. Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations Mol. Genet. Metab. 2011, 103:268-274.
25. Munoz-Rojas M.V., Vieira T., Costa R., Fagondes S., John A., Jardim L.B., Vedolin L.M., Raymundo M., Dickson P.I., Kakkis E., Giugliani R. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am. J. Med. Genet. A 2008, 146A:2538-2544.
26. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol. Genet. Metab. 2007, 91:61-68.